Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide with Docetaxel or Cabazitaxel in mCRPC
NCT05762536Phase 2Recruiting
- Sponsor
- Erasmus MC
- Start
- Nov 2023
- Primary completion
- May 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of darolutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Erasmus MC. Started Nov 2023; status: recruiting.
02
Drugs
darolutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05762536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05762536.